X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs NOVARTIS - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD NOVARTIS ALEMBIC LTD/
NOVARTIS
 
P/E (TTM) x 52.1 378.1 13.8% View Chart
P/BV x 2.2 33.3 6.7% View Chart
Dividend Yield % 0.5 1.4 33.3%  

Financials

 ALEMBIC LTD   NOVARTIS
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
NOVARTIS
Mar-18
ALEMBIC LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs72758 9.5%   
Low Rs34579 5.9%   
Sales per share (Unadj.) Rs4.7228.4 2.1%  
Earnings per share (Unadj.) Rs6.131.7 19.2%  
Cash flow per share (Unadj.) Rs6.232.8 19.1%  
Dividends per share (Unadj.) Rs0.2010.00 2.0%  
Dividend yield (eoy) %0.41.5 25.3%  
Book value per share (Unadj.) Rs40.7297.1 13.7%  
Shares outstanding (eoy) m267.0324.69 1,081.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.9 384.8%   
Avg P/E ratio x8.721.1 41.2%  
P/CF ratio (eoy) x8.520.4 41.6%  
Price / Book Value ratio x1.32.2 57.9%  
Dividend payout %3.331.5 10.4%   
Avg Mkt Cap Rs m14,13916,505 85.7%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m2071,445 14.3%   
Avg. sales/employee Rs ThNM8,441.3-  
Avg. wages/employee Rs ThNM2,163.6-  
Avg. net profit/employee Rs ThNM1,173.1-  
INCOME DATA
Net Sales Rs m1,2555,639 22.3%  
Other income Rs m3701,718 21.5%   
Total revenues Rs m1,6257,357 22.1%   
Gross profit Rs m111-63 -177.8%  
Depreciation Rs m3825 149.4%   
Interest Rs m255 3.1%   
Profit before tax Rs m4421,575 28.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24792 3.0%   
Profit after tax Rs m1,630784 208.0%  
Gross profit margin %8.9-1.1 -798.6%  
Effective tax rate %5.450.3 10.8%   
Net profit margin %129.813.9 934.4%  
BALANCE SHEET DATA
Current assets Rs m1,8679,522 19.6%   
Current liabilities Rs m5913,296 17.9%   
Net working cap to sales %101.6110.4 92.1%  
Current ratio x3.22.9 109.3%  
Inventory Days Days9437 257.4%  
Debtors Days Days7428 258.7%  
Net fixed assets Rs m1,79146 3,893.3%   
Share capital Rs m534123 432.8%   
"Free" reserves Rs m10,3247,213 143.1%   
Net worth Rs m10,8587,336 148.0%   
Long term debt Rs m410-   
Total assets Rs m11,59111,105 104.4%  
Interest coverage x260.929.5 884.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.5 21.3%   
Return on assets %14.17.6 186.3%  
Return on equity %15.010.7 140.5%  
Return on capital %15.222.2 68.3%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1961 32.0%   
Fx outflow Rs m2643,630 7.3%   
Net fx Rs m-244-3,570 6.8%   
CASH FLOW
From Operations Rs m2361,610 14.6%  
From Investments Rs m-224687 -32.6%  
From Financial Activity Rs m-27-2,677 1.0%  
Net Cashflow Rs m-15-380 3.9%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 2.0 10.0%  
FIIs % 9.7 1.6 606.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 21.5 121.4%  
Shareholders   54,701 41,647 131.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  PFIZER  ALEMBIC PHARMA  

Compare ALEMBIC LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 134 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended marginally lower. Sectoral indices ended on a mixed note with stocks.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

This Trend Will Produce a Once in a Lifetime Opportunity to Buy Stocks(The 5 Minute Wrapup)

Jan 15, 2019

Unlike his habit of pouring out stock wisdom in his annual letters to shareholders, Buffett spoke of this trend only once every few decades.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

My Next Small Cap Recommendation Is Practically a 'No Brainer'(Profit Hunter)

Jan 14, 2019

With a strong debt free balance sheet in its favour, attractive dividends and trading at almost lifetime lows, this investing idea is almost a no brainer.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Jan 22, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS